Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lipocine (LPCN) EBITDA Margin (2018 - 2025)

Historic EBITDA Margin for Lipocine (LPCN) over the last 8 years, with Q3 2025 value amounting to 2776.34%.

  • Lipocine's EBITDA Margin changed N/A to 2776.34% in Q3 2025 from the same period last year, while for Sep 2025 it was 126.79%, marking a year-over-year decrease of 729600.0%. This contributed to the annual value of 0.09% for FY2024, which is 5727200.0% up from last year.
  • According to the latest figures from Q3 2025, Lipocine's EBITDA Margin is 2776.34%.
  • In the past 5 years, Lipocine's EBITDA Margin registered a high of 4915.75% during Q1 2021, and its lowest value of 6995.38% during Q1 2023.
  • Its 5-year average for EBITDA Margin is 1212.09%, with a median of 355.22% in 2025.
  • In the last 5 years, Lipocine's EBITDA Margin surged by 70412700bps in 2024 and then tumbled by -20365300bps in 2025.
  • Over the past 5 years, Lipocine's EBITDA Margin (Quarter) stood at 78.39% in 2021, then crashed by -776bps to 529.85% in 2022, then skyrocketed by 297bps to 1045.61% in 2023, then plummeted by -95bps to 51.02% in 2024, then tumbled by -5541bps to 2776.34% in 2025.
  • Its last three reported values are 2776.34% in Q3 2025, 355.22% for Q2 2025, and 1990.64% during Q1 2025.